| CTAS |
Report |
Organic Growth Rate (Q4 FY26) |
BEAT |
pred ~7.8% vs. cons 7.3% |
MEDIUM |
| CTAS |
Report |
Gross Margin % (Q4 FY26) |
IN-LINE |
pred ~50.3% vs. cons 50.2% |
MEDIUM |
| CTAS |
Report |
Adj. Diluted EPS (Q4 FY26) |
IN-LINE |
pred ~$1.25 vs. cons $1.24 |
MEDIUM |
| CTAS |
Guide |
Revenue (FY2026 - maintain) |
UNCHANGED |
guide ~$11.21-11.24B vs. cons $11,232M |
HIGH |
| CTAS |
Guide |
Adj. EPS (FY2026 - maintain) |
UNCHANGED |
guide ~$4.86-4.90 vs. cons $4.89 |
HIGH |
| CTAS |
Guide |
Revenue (FY2027 - initial) |
UNCHANGED |
guide ~$12.00-12.15B (mid $12.075B) vs. cons $12,069M |
MEDIUM |
| CTAS |
Guide |
Adj. EPS (FY2027 - initial) |
UNCHANGED |
guide ~$5.35-5.45 (mid $5.40) vs. cons $5.42 |
MEDIUM |
| CTAS |
Guide |
Qualitative: UniFirst/FTC tone |
UNCHANGED |
cautiously constructive; no new timeline acceleration |
LOW |
| CTAS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
MEDIUM |
| CTAS |
Return |
5-day cumulative residual |
+0.8% (STABILIZE) |
STABILIZE - Archetype B follow-through; FY27 in-line guide gives sell-side little reason to revise; FTC overhang caps upside |
MEDIUM |